Clinical Trial Update: A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093 [Phase 1]

View source ↗

Summary

A Phase 1 double-blind, randomized, placebo-controlled, rising multiple-dose study assessed safety, tolerability, steady-state pharmacokinetics and CNS effects …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• BIA 2-093

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Epilepsy | Phase 1 | Status: COMPLETED | Results posted: 2015-01-07